Are we undermining the value of palliative care through advanced cancer clinical trial consent language?-Reference-Cited by-同舟云学术

Are we undermining the value of palliative care through advanced cancer clinical trial consent language?

Published:2021-03-10 Issue:12 Volume:127 Page:1954-1956
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Umaretiya Puja J.¹²³^ORCID,Rubin Jennifer P.⁴,Snaman Jennifer M.¹²³^ORCID,Ullrich Christina¹²³^ORCID,Feraco Angela M.¹²^ORCID,Dussel Veronica²⁵,Wolfe Joanne²³,Waldman Elisha⁶

Affiliation:

1. Department of Pediatric Oncology Dana‐Farber Cancer Institute Boston Massachusetts

2. Division of Pediatric Hematology/Oncology Boston Children's Hospital Boston Massachusetts

3. Department of Psychosocial Oncology and Palliative Care Dana‐Farber Cancer Institute Boston Massachusetts

4. Department of Pediatric Neurology Northwestern Feinberg School of Medicine Chicago Illinois

5. Centro de Investigación e Implementación en Cuidados Paliativos Instituto de Efectividad Clínica y Sanitaria Buenos Aires Argentina

6. Division of Palliative Care Ann and Robert H. Lurie Children's Hospital of Chicago Chicago Illinois

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33482

Reference27 articles.

1. Cancer Therapy Evaluation Program.Informed consent. Accessed October 26 2020.https://ctep.cancer.gov/protocolDevelopment/informed_consent.htm

2. Investigator Disclosure and Advanced Cancer Patient Understanding of Informed Consent and Prognosis in Phase I Clinical Trials

3. Food and Drug Administration.Informed consent. Accessed November 18 2020.https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/informed‐consent#requirementsdiscussion

4. World Health Organization.Palliative care. Accessed October 26 2020.https://www.who.int/cancer/palliative/definition/en/

5. Generalist plus Specialist Palliative Care — Creating a More Sustainable Model